646 related articles for article (PubMed ID: 32512263)
1. COVID-19 in rheumatic disease patients on immunosuppressive agents.
Sharmeen S; Elghawy A; Zarlasht F; Yao Q
Semin Arthritis Rheum; 2020 Aug; 50(4):680-686. PubMed ID: 32512263
[TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
[TBL] [Abstract][Full Text] [Related]
3. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
4. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
5. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
6. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
Misra DP; Agarwal V; Gasparyan AY; Zimba O
Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
[TBL] [Abstract][Full Text] [Related]
7. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
[TBL] [Abstract][Full Text] [Related]
8. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
9. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
10. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M
Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
D'Silva KM; Serling-Boyd N; Wallwork R; Hsu T; Fu X; Gravallese EM; Choi HK; Sparks JA; Wallace ZS
Ann Rheum Dis; 2020 Sep; 79(9):1156-1162. PubMed ID: 32457048
[TBL] [Abstract][Full Text] [Related]
12. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S
Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399
[TBL] [Abstract][Full Text] [Related]
13. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
15. Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19 in a New York Hospital and Predictors of ICU Care and Ventilation.
Singer AJ; Morley EJ; Meyers K; Fernandes R; Rowe AL; Viccellio P; Thode HC; Bracey A; Henry MC
Ann Emerg Med; 2020 Oct; 76(4):394-404. PubMed ID: 32563601
[TBL] [Abstract][Full Text] [Related]
16. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
[TBL] [Abstract][Full Text] [Related]
17. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
Perricone C; Triggianese P; Bartoloni E; Cafaro G; Bonifacio AF; Bursi R; Perricone R; Gerli R
J Autoimmun; 2020 Jul; 111():102468. PubMed ID: 32317220
[TBL] [Abstract][Full Text] [Related]
18. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study.
Lund LC; Kristensen KB; Reilev M; Christensen S; Thomsen RW; Christiansen CF; Støvring H; Johansen NB; Brun NC; Hallas J; Pottegård A
PLoS Med; 2020 Sep; 17(9):e1003308. PubMed ID: 32898149
[TBL] [Abstract][Full Text] [Related]
19. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study.
So H; Mak JW; So J; Lui G; Lun F; Lee J; Chan S; Ho C; Chan JM; Kong SP; Ng WL; Tam LS
Semin Arthritis Rheum; 2020 Oct; 50(5):885-889. PubMed ID: 32896705
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
